Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.

Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.

<h4>Background</h4>Brain volume loss is an important surrogate marker for assessing disability in MS; however, contribution of gray and white matter to the whole brain volume loss needs further examination in the context of specific MS treatment.<h4>Objectives</h4>To examine...

Full description

Bibliographic Details
Main Authors: Fredrika Koskimäki, Jacqueline Bernard, Jeong Yong, Nancy Arndt, Timothy Carroll, Seon-Kyu Lee, Anthony T Reder, Adil Javed
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0209326

Internet

https://doi.org/10.1371/journal.pone.0209326

Similar Items